You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAripiprazole
Accession NumberDB01238  (APRD00638)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Structure
Thumb
Synonyms
SynonymLanguageCode
AbilifyNot AvailableNot Available
AbilitatNot AvailableNot Available
AripiprazolNot AvailableNot Available
AripiprazoleNot AvailableNot Available
AripiprazolumNot AvailableNot Available
OPC 31Not AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet2 mgoralSTAT Rx USA LLC2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralSTAT Rx USA LLC2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralRebel Distributors Corp.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralRebel Distributors Corp.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralRebel Distributors Corp.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralRebel Distributors Corp.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralREMEDYREPACK INC.2013-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralREMEDYREPACK INC.2013-04-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralREMEDYREPACK INC.2013-04-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet30 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralAphena Pharma Solutions Tennessee, Llc2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralAphena Pharma Solutions Tennessee, Llc2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet30 mgoralAphena Pharma Solutions Tennessee, Llc2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralLake Erie Medical DBA Quality Care Products LLC2010-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralH.J. Harkins Company, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralPhysicians Total Care, Inc.2006-01-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralPhysicians Total Care, Inc.2011-07-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet30 mgoralCardinal Health2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralPd Rx Pharmaceuticals, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet20 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet30 mgoralOtsuka America Pharmaceutical, Inc.2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifysolution1 mg/mLoralOtsuka America Pharmaceutical, Inc.2004-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifyinjection, solution9.75 mg/1.3mLintramuscularOtsuka America Pharmaceutical, Inc.2006-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify DISCMELTtablet, orally disintegrating10 mgoralOtsuka America Pharmaceutical, Inc.2006-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilify DISCMELTtablet, orally disintegrating15 mgoralOtsuka America Pharmaceutical, Inc.2006-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralbryant ranch prepack2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralbryant ranch prepack2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralbryant ranch prepack2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralTYA Pharmaceuticals2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralTYA Pharmaceuticals2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralTYA Pharmaceuticals2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet10 mgoralTYA Pharmaceuticals2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralCarilion Materials Management2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet5 mgoralCarilion Materials Management2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2 mgoralCarilion Materials Management2002-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet2.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Abilifytablet5.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Abilifytablet10.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Abilifytablet15.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Abilifytablet20.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Abilifytablet30.0 mgoralBristol Myers Squibb CanadaNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet10 mgoralREMEDYREPACK INC.2010-12-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet30 mgoralREMEDYREPACK INC.2010-12-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Abilifytablet15 mgoralREMEDYREPACK INC.2010-12-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AbilitatNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number129722-12-9
WeightAverage: 448.385
Monoisotopic: 447.148032537
Chemical FormulaC23H27Cl2N3O2
InChI KeyCEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Quinolone
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Substituted aniline
  • Dialkylarylamine
  • 1,2-dichlorobenzene
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsAripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionAripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
AbsorptionNot Available
Volume of distribution
  • 4.9 L/kg
Protein binding>99%
Metabolism

Hepatic.

Route of eliminationLess than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
Half life75-146 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 substrateInhibitor0.6682
CYP450 2D6 substrateInhibitor0.6633
CYP450 2C19 substrateInhibitor0.8934
CYP450 3A4 substrateInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular9.75 mg/1.3mL
Kit
Solutionoral1 mg/mL
Tabletoral10 mg
Tabletoral10.0 mg
Tabletoral15 mg
Tabletoral15.0 mg
Tabletoral2 mg
Tabletoral2.0 mg
Tabletoral20 mg
Tabletoral20.0 mg
Tabletoral30 mg
Tabletoral30.0 mg
Tabletoral5 mg
Tabletoral5.0 mg
Tablet, orally disintegratingoral10 mg
Tablet, orally disintegratingoral15 mg
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States50065281994-10-202014-10-20
United States71155872005-01-212025-01-21
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceUS5006528
General ReferenceNot Available
External Links
ATC CodesN05AX12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (262 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AcetaminophenCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AcetazolamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AcetohexamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AlmotriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
AlogliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AmisulprideAntipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.
AmitriptylineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
AmlodipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AmoxapineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
AmphetamineMay diminish the stimulatory effect of Amphetamines.
AnastrozoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AprepitantCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
armodafinilCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ArtemetherCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
AtomoxetineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AtorvastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
BenzphetamineMay diminish the stimulatory effect of Amphetamines.
BetaxololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
BicalutamideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
BiotinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
BoceprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
BortezomibCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
BosentanCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
BuprenorphineCNS Depressants may enhance the CNS depressant effect of Buprenorphine.
BupropionCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
BuspironeSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ButalbitalCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CabergolineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
CalcitriolCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
CanagliflozinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CarbamazepineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
CarfilzomibCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CathinoneAntipsychotic Agents may diminish the stimulatory effect of Amphetamines.
CelecoxibCYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
ChloroquineCYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
ChlorphenamineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ChlorpromazineCYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
ChlorpropamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ChlorzoxazoneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CholecalciferolCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CimetidineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
CinacalcetCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
CitalopramSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ClarithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
ClemastineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ClobazamCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ClomipramineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ClotrimazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
ClozapineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CocaineCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
CrizotinibCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
CrofelemerCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
CyclobenzaprineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
CyclophosphamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
Cyproterone acetateCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DalfopristinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DanazolCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DarifenacinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
DelavirdineCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
DesipramineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
DesogestrelCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DesvenlafaxineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
DextroamphetamineMay diminish the stimulatory effect of Amphetamines.
DextromethorphanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
DiazepamCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DicloxacillinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
DihydrocodeineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DihydroergotamineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
DiltiazemCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
DisulfiramCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DocetaxelCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DolasetronCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DonepezilAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
DoxycyclineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
DoxylamineMay enhance the CNS depressant effect of CNS Depressants.
DronabinolMay enhance the CNS depressant effect of CNS Depressants.
DroperidolMay enhance the CNS depressant effect of CNS Depressants.
DrospirenoneCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
DuloxetineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
EletriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
EntacaponeCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
EnzalutamideCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
Ergoloid mesylateSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ErgonovineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ErgotamineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
EribulinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
EscitalopramSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
Ethinyl EstradiolCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
EthynodiolCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
EtoposideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
EtravirineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ExemestaneCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
FelbamateCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
FelodipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
FentanylSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
FexofenadineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
FlecainideCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
FluconazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
FluoxetineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
FluvastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
FluvoxamineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
FosaprepitantCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
FosphenytoinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
FrovatriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
GalantamineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
GefitinibCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
GliclazideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlimepirideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GliquidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlyburideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
Glycerol PhenylbutyrateCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
GriseofulvinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
HaloperidolMay enhance the QTc-prolonging effect of Haloperidol. ARIPiprazole may diminish the therapeutic effect of Haloperidol. Haloperidol may increase the serum concentration of ARIPiprazole.
HydralazineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
HydrocodoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydroxyzineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
IfosfamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ImipramineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
Insulin AspartHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin DetemirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlargineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlulisineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin LisproHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin RegularHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin, isophaneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
IrbesartanCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
IsavuconazoniumCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
IsocarboxazidSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
IsomethepteneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
IsoniazidCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
IsradipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ItraconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
LansoprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LapatinibCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LevomilnacipranSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
LinagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LinezolidSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
LisdexamfetamineMay diminish the stimulatory effect of Amphetamines.
LithiumMay enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.
LomitapideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
LomustineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LopinavirMay enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia, weight gain, hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.
LoratadineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LorcaserinSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
LosartanCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LovastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
LumefantrineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
LurasidoneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
Magnesium SulfateMay enhance the CNS depressant effect of CNS Depressants.
MaprotilineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
Medroxyprogesterone AcetateCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
MefloquineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MequitazineAntipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.
MestranolCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MetforminHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MethadoneSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
MethamphetamineMay diminish the stimulatory effect of Amphetamines.
MethimazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MethotrimeprazineCNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.
MethylergometrineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
MethylphenidateMay enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.
MethylprednisoloneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MetoclopramideMetoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents.
MetoprololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MetyraponeCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
MetyrosineMetyrosine may enhance the adverse/toxic effect of Antipsychotic Agents.
MicafunginCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MidazolamCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MilnacipranSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
MirabegronCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MirtazapineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
MitoxantroneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
MoclobemideSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ModafinilCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
NabiloneMay enhance the CNS depressant effect of CNS Depressants.
NafcillinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
NaratriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
NefazodoneSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
NevirapineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
NifedipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
NisoldipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
NizatidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
NorelgestrominCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
NorfloxacinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
NorgestimateCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
NortriptylineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
OlanzapineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
OmeprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
OndansetronCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
OritavancinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
OrphenadrineCNS Depressants may enhance the CNS depressant effect of Orphenadrine.
OspemifeneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
OxcarbazepineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
OxybutyninCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PanobinostatMay increase the serum concentration of CYP2D6 Substrates.
ParoxetineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
PazopanibCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
Peginterferon alfa-2bCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PentamidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PerampanelMay enhance the CNS depressant effect of CNS Depressants.
PerphenazineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PethidineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
PhendimetrazineMay diminish the stimulatory effect of Amphetamines.
PhenelzineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
PhenobarbitalCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
PhentermineMay diminish the stimulatory effect of Amphetamines.
PhenytoinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
PilocarpineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PindololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PioglitazoneCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
PravastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PraziquantelCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PrednisoneCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
PrimaquineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PrimidoneCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ProcarbazineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ProgesteroneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PromazineCYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
PromethazineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
PropafenoneCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PropofolCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
PropranololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ProtriptylineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
QuinidineCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
QuinupristinCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
RabeprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
RanitidineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
RanolazineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
RasagilineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
RepaglinideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
RifampicinCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
RifapentineCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
RisperidoneCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
RitonavirMay enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia, weight gain, hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.
RivastigmineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RizatriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
RufinamideCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
SaquinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
SaxagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SelegilineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
SertralineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
SildenafilCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SimvastatinCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
SirolimusCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
Sodium phenylbutyrateCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
SulconazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
SulfisoxazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
SulpirideAntipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.
SumatriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
SuvorexantCNS Depressants may enhance the CNS depressant effect of Suvorexant.
TamoxifenCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
Tedizolid PhosphateSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
TelaprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
TelithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
TemsirolimusCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TeniposideCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TetrabenazineTetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.
TetracyclineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.
ThalidomideCNS Depressants may enhance the CNS depressant effect of Thalidomide.
ThioridazineCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
ThiothixeneCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TicagrelorCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TiclopidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TimololCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TioconazoleCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TipranavirCYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolbutamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TolvaptanCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
TopiramateCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
TramadolSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
TrametinibCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
TranylcypromineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
TrimipramineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
TriprolidineCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
VemurafenibCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
VenlafaxineSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
VilazodoneSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
VildagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
VinblastineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
VincristineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
VinorelbineCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
VoriconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
ZafirlukastCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
ZolmitriptanSerotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
ZolpidemCNS Depressants may enhance the CNS depressant effect of Zolpidem.
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.

Targets

1. 5-hydroxytryptamine receptor 2A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Pubmed
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. Pubmed
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. Pubmed

2. D(2) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist partial agonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. Pubmed
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. Pubmed
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. Pubmed
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. Pubmed
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. 5-hydroxytryptamine receptor 1A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist partial agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. Pubmed
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. Pubmed
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. Pubmed
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. Pubmed
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. Pubmed

4. 5-hydroxytryptamine receptor 1B

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1B P28222 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

5. 5-hydroxytryptamine receptor 1D

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1D P28221 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

6. 5-hydroxytryptamine receptor 1E

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1E P28566 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

7. 5-hydroxytryptamine receptor 2C

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P28335 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

8. 5-hydroxytryptamine receptor 3A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 3A P46098 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

9. 5-hydroxytryptamine receptor 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 6 P50406 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

10. 5-hydroxytryptamine receptor 7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 7 P34969 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

11. D(1A) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist partial agonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

12. D(1B) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist partial agonist

Components

Name UniProt ID Details
D(1B) dopamine receptor P21918 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

13. D(3) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist partial agonist

Components

Name UniProt ID Details
D(3) dopamine receptor P35462 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

14. D(4) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist partial agonist

Components

Name UniProt ID Details
D(4) dopamine receptor P21917 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

15. Histamine H1 receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

16. Alpha-1A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

17. Alpha-1B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

18. Alpha-2A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

19. Alpha-2B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2B adrenergic receptor P18089 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

20. Alpha-2C adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist other/unknown

Components

Name UniProt ID Details
Alpha-2C adrenergic receptor P18825 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

21. Muscarinic acetylcholine receptor M1

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M1 P11229 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

22. Muscarinic acetylcholine receptor M2

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M2 P08172 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

23. Muscarinic acetylcholine receptor M3

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M3 P20309 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

24. Muscarinic acetylcholine receptor M4

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M4 P08173 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

25. Muscarinic acetylcholine receptor M5

Kind: protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M5 P08912 Details

References:

  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 10, 2014 12:38